leadf
logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics on the potential of peanut vaccine

An Allergy Therapeutics (LON:AGY) breakthrough has the potential to protect against severe allergic reactions to peanuts, according to research carried by a leading academic journal.  

The single injection helped mice generate “sustained immunity and protection through vaccination”, helping prevent anaphylaxis.

CFO Nick Wykeman and CEO Manuel Llobet are pretty excited about the firm's early stage study and have a strong cash base to work from.
The data from the firm’s early-stage study was carried in The Journal of Allergy and Clinical Immunology, or JACI for short.

The first clinical trials of the vaccine are expected to get underway over the summer.
 

Quick facts: Allergy Therapeutics PLC

Price: 14.56 GBX

AIM:AGY
Market: AIM
Market Cap: £93.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: Weaker pound steers FTSE higher, while Tesla drives investors...

The FTSE is higher this Wednesday. One of the main talking points today - is Tesla (NASDAQ: TSLA) after much anticipation leading up to CEO Elon Musk’s announcement - it failed to impress - slashing $50 billion from Tesla's market value after a promise to cut electric vehicle costs so...

3 weeks, 6 days ago

2 min read